Friday, September 10, 2010
"The source for European pharmaceutical biotechnology news..."
Looming patent cliffs and shrivelling pipelines have pharma's big players looking for new business models that will allow them to increase their bottom lines.
Issue 8 Executive Interviews
Starting at phase zero
Michael Butler of Xceleron looks at the value a microdose study adds to a drug development programme.
No Comments
The future of biomarker assays
Ralph McDade of Rules Based Medicine explains why more is better when it comes to data used to identify meaningful biomaker patterns.
No Comments
Medical communications in a changing world
Amanda Smith of Caudex Medical explains the effects of the movement towards evidence-based medicine.
No Comments
Moving ahead in medical communications
David Swinbanks tells NGP about Nature Publishing Group’s recent move into medical communications with its new division, Macmillan Medical Communications.
No Comments
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.